Now accepting new Members for precision longevity programs.Learn more
Longevity Therapeutics 7 min read
HBOT for Longevity: What the Tel Aviv Telomere Study Actually Found
Dr. R. Brahmananda Reddy
7 April 2026
Knowledge Hub
Dr. R. Brahmananda Reddy
7 April 2026
In November 2020, a research team led by Professor Shai Efrati at Tel Aviv University and the Shamir Medical Center published a study that sent shockwaves through the longevity medicine community. Published in the journal Aging, the findings were striking: hyperbaric oxygen therapy (HBOT) had, for the first time in a controlled human trial, reversed two hallmark biological processes of ageing — telomere shortening and the accumulation of senescent cells.
The headline numbers were remarkable. But in an era of breathless health claims, the responsible question is not "what did they claim?" but "what did they actually find, how did they find it, and does it hold up?" Let me walk you through the science.
Before examining the study, it helps to understand why telomeres and senescent cells matter.
Telomeres are repetitive DNA sequences (TTAGGG, repeated thousands of times) that cap the ends of your chromosomes. Think of them as the plastic aglets on shoelaces — they prevent the ends from fraying. Every time a cell divides, telomeres shorten slightly. When they become critically short, the cell can no longer divide safely. It either dies (apoptosis) or enters a state of permanent growth arrest called senescence.
Telomere length is therefore a biomarker of cellular ageing. Shorter telomeres are associated with increased risk of cardiovascular disease, cancer, diabetes, and all-cause mortality. The rate at which telomeres shorten varies dramatically between individuals and is influenced by genetics, stress, inflammation, sleep quality, exercise, and nutrition.
When cells become damaged or reach the end of their replicative capacity, they should ideally be cleared by the immune system. But with age, this clearance process becomes less efficient. Damaged cells that should have been eliminated instead persist in a state called cellular senescence — they are alive but no longer dividing.
The problem is that senescent cells are not passive. They secrete a cocktail of inflammatory molecules, growth factors, and proteases collectively called the SASP (senescence-associated secretory phenotype). This secretory profile damages neighbouring healthy cells, promotes chronic inflammation, and accelerates tissue ageing. Senescent cells are sometimes called "zombie cells" because they are neither fully alive nor dead, and they harm everything around them.
Reducing the senescent cell burden — a process called senolysis — is one of the most active areas of longevity research globally.
The study enrolled 35 healthy, independently living adults aged 64 and older. This was a prospective trial — meaning it tracked outcomes forward in time — with participants serving as their own controls (pre-treatment measurements compared to post-treatment measurements).
Participants received 60 daily HBOT sessions over approximately three months. Each session involved:
Whole blood samples were collected at four time points:
Blood samples were analysed for telomere length in specific immune cell populations and for the percentage of senescent cells.
Telomere length increased significantly across multiple immune cell types:
The overall finding: telomeres lengthened by 20% to 38% depending on cell type. This is not a subtle shift — it represents a reversal of what was previously considered an irreversible process.
The reduction in senescent cells was equally striking:
These reductions represent a meaningful clearance of the "zombie cells" that drive chronic inflammation and tissue deterioration.
HBOT's effects on ageing are counterintuitive. One might expect that flooding cells with oxygen would increase oxidative damage. The key insight from the Efrati team is that it is not the high oxygen itself that drives the therapeutic effect — it is the repeated cycling between hyperoxia and relative normoxia.
This cycling triggers what researchers describe as the hyperoxic-hypoxic paradox. When you breathe pure oxygen at elevated pressure, tissues become saturated. When you then switch to breathing normal air (the air breaks in the protocol), the relative drop in oxygen — even though it is still normal atmospheric levels — is perceived by cells as a hypoxic signal.
This intermittent "hypoxic" signalling activates a cascade of regenerative processes:
As a comprehensive 2024 review published in Frontiers in Aging noted, HBOT affects physiological processes at the genetic level by altering gene expression, delaying cell senescence, and assisting in telomere length enhancement.
One of the most important questions about any therapeutic intervention is durability. A treatment that produces impressive short-term results but fades within weeks has limited clinical value.
A follow-up study published in Nature Scientific Reports tracked the same participants more than one year after treatment ended. The findings were encouraging: telomere length remained elevated, and senescent cell reduction was maintained, suggesting lasting cellular renewal rather than a transient effect.
This durability is significant because it implies that HBOT may not simply be delaying the ageing process temporarily but potentially resetting certain aspects of cellular biology to a younger state.
As with any groundbreaking study, honest assessment requires acknowledging limitations:
Despite these limitations, the biological plausibility of the mechanism and the statistical significance of the results make this a study that deserves serious attention, not dismissal.
The Efrati telomere study is the most widely cited HBOT longevity study, but it exists within a broader evidence base:
A review paper published in Frontiers in Aging (2024) concluded that despite evidence supporting its efficacy in modulating biological ageing markers, HBOT remains underrepresented in longevity medicine discourse — a gap that is beginning to close as more clinical data emerges.
HBOT is not a standalone longevity solution. No single intervention is. But the Efrati study demonstrates that HBOT, delivered in a specific, evidence-based protocol, can produce measurable changes in two of the most fundamental biomarkers of ageing: telomere length and senescent cell burden.
In a comprehensive longevity programme, HBOT serves as a powerful adjunct to the foundational pillars of exercise, nutrition, sleep, stress management, and biomarker-guided medical optimisation. It addresses ageing at the cellular level in a way that lifestyle interventions alone may not fully achieve.
The caveat — and it is an important one — is that HBOT must be delivered in a clinical setting with medical-grade equipment, proper protocols, and physician oversight. The specific parameters matter: pressure, duration, oxygen concentration, air break timing, and total number of sessions all influence outcomes.
The Tel Aviv telomere study represents a frontier — not a final answer. It demonstrates that biological ageing, at least at the cellular level, is more malleable than we previously believed. Telomeres can be lengthened. Senescent cells can be cleared. And these changes can persist.
For anyone interested in longevity, the study's core message is profoundly hopeful: the biological clock is not as fixed as we once thought. With the right interventions, measured by the right biomarkers, guided by evidence rather than hype, it is possible to influence how your cells age.
At Genoryx, we measure what your annual checkup misses — including telomere length, senescent cell markers, and the biomarkers of cellular ageing that reveal your true biological status. Our physician-guided HBOT protocols are based on the same evidence-based parameters used in published clinical research. Book your consultation and learn how cellular regeneration therapy fits into your longevity plan.
Book your 400+ biomarker assessment — physician consultation included.
Schedule a consultationReady to know your numbers?
Schedule your consultation with our longevity physician team.
Book Your AssessmentWritten by
UK-trained physician and founder of Genoryx. Writes about longevity medicine, healthspan optimization, and evidence-based wellness.
View profile →
NAD+ declines by up to 50% between your twenties and fifties, driving fatigue, cognitive decline, and accelerated aging. Three strategies claim to restore it: NMN supplements, NR supplements, and IV NAD+ infusions.
NAD+ levels decline by up to 50% by middle age, crippling your mitochondria's ability to produce energy. Here is what the latest clinical research says about restoring this critical coenzyme — and what it means for ageing, cognition, and cellular repair.